STOCKS TELEGRAPH

Tag: Histogen stock

  • Has Histogen (HSTO) Stock Risen in Extended Session For A Reason?

    Has Histogen (HSTO) Stock Risen in Extended Session For A Reason?

    The shares of Histogen Inc. (HSTO) rose 5.87% to $0.8799 in Friday’s after-hours trading. At the end of the regular trading session, Histogen stock closed at $0.83, down -1.01%. The volume of shares traded on HSTO stock was 0.44 million, which is below the average daily trading volume of 1.89 million shares for the past 50 days.

    In the last five days, HSTO stock has declined -14.27%, but over the past month, they have lost -17.71%. The HSTO stock price has fallen by -19.31% over the past three months and is down by -72.11 percent year-to-date. Due to the HSTO stock’s rise in the absence of current news, developments have been observed that lend clarity to HSTO’s current situation.

    Have things been going well at HSTO lately?

    In addition to developing potential first-in-class restorative therapeutics, Histogen engages the body’s natural mechanisms for repairing and maintaining healthy biological function. Hypoxia-induced multipotent cells produce cell conditioned media and extracellular matrix materials for HSTO’s innovative technology platform. With its proprietary, reproducible manufacturing process, HSTO offers tailored solutions across a wide range of therapeutic indications, including joint cartilage regeneration, spinal disk repair, and dermal rejuvenation.

    Histogen recently announced that it will begin testing its HST 003 in Phase 1/2 clinical trials.

    • Human extracellular matrix (hECM:HST 0003) was implanted within microfracture interstices or cartilage defects in the knee in order to restore hyaline cartilage in conjunction with a microfracture procedure in the HSTO trial.
    • Walter Reed Medical Center in Bethesda, MD, The Steadman Clinic in Vail, CO, and OasisMD in San Diego, CA, are participating in HSTO’s trial.
    • By using a novel scaffold that stimulates the body’s own stem cells, HSTO’s hECM aims to regenerate hyaline cartilage for the treatment of articular cartilage defects.
    • A number of preclinical studies have demonstrated that HST 003 regenerates mature cartilage and well-vascularized bone, which suggests great therapeutic potential in sports medicine, spinal disc repair, orthopedic, and dental fields.
    • HSTO’s double-blind placebo-controlled trial aims to evaluate whether hECM can regenerate hyaline cartilage in combination with microfracture in microfracture interstices and cartilage defects in the knee.
    • Safety assessments, MRI scans to check for cartilage regeneration, and Knee Injury and Osteoarthritis Outcome Score (KOOS) and International Knee Documentation Committee (IKDC) scores will serve as primary and secondary endpoints, respectively.

    The trial will help HSTO grow in what ways?

    A significant milestone has been achieved for Histogen (HSTO) with the initiation of the HST 003 clinical trial. With the trial, HSTO will continue to work on developing top-of-the-line orthopedic therapeutics based on its regenerative medicine platform technology.

  • 32 Stocks Making Sharp Moves in Pre Market Session

    32 Stocks Making Sharp Moves in Pre Market Session

    Sundial Growers Inc. (SNDL) stock soared 1.72% to $0.5088 in the pre-market trading after declaring $50 million prepayment on senior secured non-revolving term credit facility. The most recent rating by CIBC, on August 17, 2020, is a Neutral.

    FuelCell Energy Inc. (FCEL) is up more than 2.09% at $8.31 in pre-market hours Wednesday December 16, 2020. The stock had jumped over 5.71% to $8.14 in the last trading session.

    BioCardia Inc. (NASDAQ: BCDA) shares are trading up 5.22% at $7.05 at the time of writing after reporting that it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share Company’s 52-week ranged between $1.91 to $6.95.

    Before the trading started on December 16, 2020, MicroVision Inc. (MVIS) is down -1.9% to reach $4.13. It has been trading in a 52-week range of $0.15 to $3.45.

    Apartment Investment and Management Company (AIV) tumbled over -6.75% at $4.7 in pre-market trading today following completion of separation of Apartment Income REIT Corp.

    Before the trading started on December 16, 2020, GeoVax Labs Inc. (GOVX) is down -7.86% to reach $3.4. It has been trading in a 52-week range of $2.30 to $60.00.

    Anchiano Therapeutics Ltd. (ANCN), a Biotechnology company, dropped about -7.99% at $2.65 in pre-market trading Wednesday after the company and and Chemomab Ltd. declared their entry into a definitive merger agreement.

    BEST Inc. (NYSE: BEST) shares are trading up 3.29% at $2.2 at the time of writing. Company’s 52-week ranged between $2.36 to $6.54. Analysts have a consensus price target of $3.50.

    Veru Inc. (VERU) stock moved down -7.5 percent to $8.63 in the pre-market trading. The company lately reported positive Phase 2 clinical trial results for Enobosarm.

    Northern Dynasty Minerals Ltd. (NAK) is up more than 3.67% at $0.325 in pre-market hours Wednesday December 16, 2020. The stock had dropped over -4.74% to $0.31 in the last trading session.

    Moderna Inc. (MRNA) stock plunged -3.33% to $142.32 in the pre-market trading. The company recently confirmed supply agreement with the Ministry of Health to supply Singapore with mRNA vaccine against COVID-19 (mRNA-1273). The most recent rating by Needham, on December 09, 2020, is a Hold.

    Before the trading started on December 16, 2020, Teligent Inc. (TLGT) is up 2.2% to reach $0.93. It has been trading in a 52-week range of $0.46 to $6.46.

    HEXO Corp. (HEXO), a Drug Manufacturers – Specialty & Generic company, rose about 2.75% at $1.12 in pre-market trading Wednesday. The firm recently revealed it first quarter fiscal 2021 financial results.

    Gevo Inc. (NASDAQ: GEVO) shares are trading up 4.74% at $1.99 at the time of writing. Company’s 52-week ranged between $0.46 to $2.91.

    Timber Pharmaceuticals Inc. (TMBR) stock moved down -0.97 percent to $1.02 in the pre-market trading after receiving notice of allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001.

    Baidu Inc. (BIDU) is up more than 4.33% at $193.53 in pre-market hours Wednesday December 16, 2020. The stock had jumped over 13.83% to $185.50 in the last trading session.

    Aurora Cannabis Inc. (ACB) gained over 1.76% at $10.39 in pre-market trading Wednesday December 16, 2020 after provided a business update.

    Velodyne Lidar Inc. (VLDR) stock soared 3.91% to $20.2 in the pre-market trading after declaring a sales agreement for Alpha Prime sensors with May Mobility, a pioneer in autonomous vehicle (AV) technology. The most recent rating by Needham, on December 15, 2020, is a Buy.

    Before the trading started on December 16, 2020, Nikola Corporation (NKLA) is up 3.64% to reach $17.08. It has been trading in a 52-week range of $10.29 to $93.99.

    PG&E Corporation (NYSE: PCG) shares are trading up 2.87% at $12.55 at the time of writing after paying over $268 million in property taxes to 50 California counties. Company’s 52-week ranged between $6.25 to $18.34. Analysts have a consensus price target of $15.

    SELLAS Life Sciences Group Inc. (SLS) tumbled over -3.72% at $6.99 in pre-market trading today. The firm recently reported the pricing of $16.2 million registered direct offering.

    Nxt-ID Inc. (NASDAQ: NXTD) shares are trading down -1.66% at $0.4795 at the time of writing. Company’s 52-week ranged between $0.21 to $0.89.

    Qualigen Therapeutics Inc. (QLGN), a Biotechnology company, rose about 1.23% at $4.12 in pre-market trading Wednesday following its announcement of issuance of U.S. Patent for expanded applications of ALAN Anticancer Platform Technology.

    Concord Medical Services Holdings Limited (CCM) lost over -30.32% at $3.7 in pre-market trading Wednesday December 16, 2020.

    Aphria Inc. (APHA) grew over 11.45% at $9.05 in pre-market trading today following its declaration of definitive agreement with Tilray, Inc. (TLRY), to combine their businesses and create the world’s largest global cannabis company.

    Before the trading started on December 16, 2020, Hecla Mining Company (HL) is up 5.9% to reach $5.74. It has been trading in a 52-week range of $1.40 to $6.79.

    Twitter Inc. (TWTR), a Internet Content & Information company, rose about 3.1% at $54.46 in pre-market trading Wednesday after the declaration from the Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (AMZN), that Twitter (TWTR) has selected AWS to provide global cloud infrastructure to deliver Twitter timelines.

    Torchlight Energy Resources Inc. (TRCH) stock plunged -4.63% to $0.5332 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.

    Arvinas Inc. (ARVN) is up more than 1.41% at $75.3 in pre-market hours Wednesday December 16, 2020 after reporting the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 per share, before underwriting discounts and commissions.

    Cinedigm Corp. (CIDM) stock plunged -0.54% to $0.84 in the pre-market trading. The most recent rating by The Benchmark Company, on July 07, 2020, is a Speculative buy.

    PDL BioPharma Inc. (PDLI) grew over 6.59% at $2.75 in pre-market trading today. The company recently reported that it has entered into a Capital Provision Agreement with Epps Investments LLC.

    vTv Therapeutics Inc. (VTVT) is down more than -31.99% at $2.02 in pre-market hours Wednesday December 16, 2020 after revealing that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog14) relative to placebo.